ARTICLE | Finance
An acute arrhythmia alternative
What arrhythmia play Laguna plans to do with $30M B round
February 23, 2015 8:00 AM UTC
Laguna Pharmaceuticals Inc. plans to use a $30 million series B round to conduct a confirmatory Phase III trial of vanoxerine for acute treatment of atrial fibrillation and atrial flutter. The company is initially targeting the inpatient setting; however, Laguna and its investors believe more value will come from outpatient use.
Versant Ventures and Frazier Healthcare co-led the round. Fellow new investor BioMed Ventures participated, along with existing investor Santé Ventures. ...